==Dova Pharmaceuticals (DOVA) and Bausch Health (BHC) : agreement to co-promote Dova's DOPTELET in the US

Dova Pharmaceuticals and Bausch Health (BHC) enter agreement to co-promote Dova's DOPTELET in the US
As part of the co-promotion arrangement, Salix intends to deploy approximately 100 sales specialists who will promote DOPTELET to gastroenterology healthcare professionals. The Salix sales force will begin selling DOPTELET in mid-October 2018. Dova will continue its commercial efforts targeting primarily hepatologists and interventional radiologists and certain other specialties. Pursuant to the agreement, Dova will pay Salix a quarterly fee based on net sales (as defined in the agreement) of DOPTELET prescribed by gastroenterologists in the U.S.